Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PRNP | P04156 | 1/20 | 0.42 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | FABP3 | P05413 | 1/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6916441 | 0.86 | TDP1 (0.59) | TDP1L3MBTL1ALDH1A1KDM4EHPGD | |
| SCHEMBL355272 | 0.84 | TDP1 (0.61) | TDP1L3MBTL1ALDH1A1KDM4EHPGD | |
| SCHEMBL570378 | 0.84 | CA12 (0.52) | TDP1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL5724714 | 0.83 | THRB (0.46) | TDP1L3MBTL1ALDH1A1KDM4EHPGD | |
| SCHEMBL22182091 | 0.82 | ALDH1A1 (0.48) | TDP1L3MBTL1ALDH1A1HPGDHSD17B10 | |
| Hydrochloric Acid SCHEMBL6113042 | 0.81 | TDP1 (0.59) | TDP1L3MBTL1ALDH1A1KDM4EHPGD | |
| Bromide SCHEMBL6113408 | 0.81 | TDP1 (0.59) | TDP1L3MBTL1ALDH1A1KDM4EHPGD | |
| SCHEMBL11466346 | 0.81 | TDP1 (0.59) | TDP1L3MBTL1ALDH1A1KDM4EHPGD | |
| SCHEMBL6913554 | 0.81 | L3MBTL1 (0.59) | TDP1L3MBTL1ALDH1A1KDM4EHPGD | |
| SCHEMBL6916435 | 0.81 | TDP1 (0.59) | TDP1L3MBTL1ALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116836081-A | Ether epoxy toughening agent and preparation method and application thereof | 中国林业科学研究院林产化学工业研究所 | 2023-10-03 | — | — | CN | claimed |
| EP-1890992-A2 | AN ENRICHMENT PROCESS USING COMPOUNDS USEFUL IN A POLYESTER PROCESS | EASTMAN CHEMICAL COMPANY (US) | 2008-02-27 | — | — | EP | claimed |
| WO-2006125158-A2 | AN ENRICHMENT PROCESS USING COMPOUNDS USEFUL IN A POLYESTER PROCESS | EASTMAN CHEMICAL COMPANY (US) | 2006-11-23 | — | — | WO | claimed |
| US-12581252-B2 | Substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors | RELAY THERAPEUTICS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260034123-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| WO-2025223904-A1 | MIXTURES OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS WITH AT LEAST ONE FURTHER PESTICIDE I | BASF SE (DE) | 2025-10-30 | — | — | WO | disclosed |
| EP-4640052-A1 | MIXTURES OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS WITH AT LEAST ONE FURTHER PESTICIDE I | BASF SE (DE) | 2025-10-29 | — | — | EP | disclosed |
| US-12440484-B2 | 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORPORATION (KR) | 2025-10-14 | — | — | US | disclosed |
| EP-4562016-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-12304913-B2 | Dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2025-05-20 | — | — | US | disclosed |
| US-20250066378-A1 | SPIRO-OXAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2025-02-27 | — | — | US | disclosed |
| US-6229011-B1 | BINDING INHIBITORS BETWEEN VASCULAR ADHESION MOLECULE-1 AND ALPHA. BETA.INTEGRIN; USEFUL FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES SUCH AS MULTIPLE SCLEROSIS, ASTHMA, AND INFLAMMATORY BOWEL DISEASE | HOFFMAN-LA ROCHE INC. | 2001-05-08 | — | — | US | disclosed |
| WO-2001027128-A1 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-04-19 | — | — | WO | disclosed |
| CN-1276789-A | 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin dependent kinases | AGOURON PHARMA (US) | 2000-12-13 | — | — | CN | disclosed |
| EP-1056732-A2 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2000-12-06 | — | — | EP | disclosed |
| EP-1005445-A1 | N-ALKANOYLPHENYLALANINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999021845-A2 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
| WO-1999010312-A1 | N-ALKANOYLPHENYLALANINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-04 | — | — | WO | disclosed |
| EP-0439585-B1 | IMMOBILISATION OF LIGANDS BY RADIO-DERIVATIZED POLYMERS | MAG GEORG MAYRHOFER & CO OHG (AT) | 1997-10-29 | — | — | EP | disclosed |
| US-5196478-A | Polystyrene, assays | EPIPHARM ALLERGIE-SERVICE GESELLSCHAFT M.B.H. (AT) | 1993-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034123-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK1, CDK20 | TDP1 2877/4885L3MBTL1 1574/4885ALDH1A1 4103/4885 |
| US-12304913-B2 | Dihydropyrrolopyrazole derivative | CBR3, SLC13A3, CYP3A5 | TDP1 4441/4885L3MBTL1 2809/4885ALDH1A1 365/4885 |
| US-12440484-B2 | 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | HDAC1, HDAC11, HDAC3 | TDP1 1872/4885L3MBTL1 2475/4885ALDH1A1 455/4885 |
| US-20250066378-A1 | SPIRO-OXAZOLONES | AVPR1A, AVPR1B, AVPR2 | TDP1 3928/4885L3MBTL1 3163/4885ALDH1A1 1228/4885 |
| US-12581252-B2 | Substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors | RORB, ROR1, RORA | TDP1 3284/4885L3MBTL1 4151/4885ALDH1A1 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.